By X. Umbrak. Henry Cogswell College. 2018.
Fair for comparison of cetirizine to Cetirizine was superior to levocetirizine levocetirizine in children ages 6 to 12 for symptoms in 1 fair-quality study purchase 525mg anacin with visa, but years discount 525 mg anacin visa. Insufficient evidence on the comparative effectiveness of other drug combinations. Urticaria Poor for comparative effectiveness No head-to-head studies. Harms For outpatients with Seasonal allergic rhinitis, Perennial allergic rhinitis or urticaria, do newer antihistamines differ in safety or adverse effects? Overall adverse Fair Rates of discontinuation due to adverse events events was low with included newer antihistamines. Sedation Fair First-generation antihistamines (diphenhydramine, chlorpheniramine) more sedating than newer-generation agents. Cetirizine and levocetirizine were more sedating than loratadine and desloratadine. Some evidence suggested that cetirizine may be more sedating than fexofenadine. There was no significant difference in reports of sedation between loratadine and fexofenadine in 1 observational study. Headache Fair Headache was reported with similar rates in cetirizine, loratadine, and fexofenadine. Cardiac effects Fair A large, fair-quality cohort study provided evidence of a significant risk of cardiac arrhythmias with cetirizine compared with non-use. A nonsignificant increase in risk was noted with loratadine. Limited evidence suggested no QTc prolongation with loratadine and fexofenadine. Bitter taste/nasal Fair Incidence was higher with azelastine than discomfort olopatadine in head-to-head trials but indirect assessment suggested minimal difference between groups. Children No head-to-head data on adverse Insufficient evidence on comparative events except 2 events in cetirizine safety. Fair-quality evidence on the safety of cetirizine and loratadine. Limited evidence on the safety of desloratadine and fexofenadine. Fair evidence that cetirizine does not significantly prolong QTc interval. Limited evidence (1 study each) that desloratadine and fexofenadine did not prolong QTc interval. Subgroups Are there subgroups of patients based on demographics (age, racial groups, gender), concomitant medications (drug-drug interactions), co-morbidities (drug-disease interactions or pregnancy), for which one newer antihistamine is more effective or associated with fewer adverse effects? Age, gender, There was insufficient evidence to We did not identify head-to-head race/ethnicity determine whether any of the comparative studies of drug interactions. Asthma or atopic Fair There were no differences in rate of dermatitis adverse events in patients with allergic rhinitis and asthma or atopic dermatitis. Pregnancy Fair There was minimal increase risk of birth defects observed with newer antihistamines in pregnant women. Newer antihistamine drug exposure in pregnant women did not significantly increase the risk of hypospadias in male infants. Abbreviations: AR, allergic rhinitis; CIU, chronic idiopathic urticaria; ECG, electrocardiogram; NS, not significant; NSD, no significant difference; PAR, perennial allergic rhinitis; QT, cardiac output; QTc, corrected QT interval for heart rate; RCT, randomized controlled trial; SAR, seasonal allergic rhinitis; SD, significant difference; TSS, total symptom score. Antihistamines Page 35 of 72 Final Report Update 2 Drug Effectiveness Review Project REFERENCES 1. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Safety and tolerability of treatments for allergic rhinitis in children. Therapeutic advantages of third generation antihistamines Expert Opin Inv Drug. Allergic rhinitis and impairment issues in schoolchildren: A consensus report. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.
Parenchymal liver metastases equals stage IV 345 GYNECOLOGY FOR LESS-RESOURCED LOCATIONS Classification/histological types CA-125 with ultrasound examination is dis- appointing even in high-risk groups (BRCA muta- Three main types of primary ovarian cancers exist discount 525 mg anacin with visa. CA-125 is not diagnostic in premenopausal Epithelial cancers are the most common and women especially if the levels are low order anacin 525mg with visa. High levels account for 80% of the cancers and are believed to of CA-125 tend to correlate with advanced stages. Ovarian Cancer Screening (UKCTOCS) was a The remainder (20%) are germ cell tumors, sex randomized controlled trial designed to assess the cord stromal tumors and cancers metastatic to the effect of screening on mortality, comparing ultra- ovaries. The most common is the serous papill- between the two strategies was not significant. Other types are endometrioid, Specificity was higher in the multimodal screening mucinous, clear cell, undifferentiated, Brenner, group resulting in fewer repeat tests and unneces- transitional cell and mixed histological types. It must be said, that the Borderline epithelial tumors or tumors of low ultrasound screening was performed by experi- malignant potential tend to remain confined to enced sonographers, and similar results may not be the ovary for long periods of time, occur in reproducible in less-developed countries. SIGNS AND SYMPTOMS Another entity that is recognized is primary Many patients with early-stage ovarian cancer do peritoneal carcinoma which simulates ovarian not have signs or symptoms and the abdominal cancer clinically, although there is usually exten- mass is diagnosed by coincidence. Patients with sive intra-abdominal disease associated with nor- advanced disease often present with vague gastro- mal sized ovaries or with tumor only on the intestinal complaints, weight loss, micturition and ovary surface. CA-125 is the most common defecation changes, abdominal distention, progres- tumor marker of epithelial ovarian cancers. Inguinal and supraclavicular lymph for mucinous ovarian carcinomas. Subclasses: dysgermino- mas, yolk sac tumors, non-gestational choriocar- ULTRASOUND FEATURES OF OVARIAN cinoma, endodermal sinus tumors, immature MALIGNANCY teratomas, polyembryomas. Tumor markers A uni- or multilocular mass with papillary struc- include: β-human chorionic gonadotropin tures and solid masses in the cysts and thick septa is (β-hCG), α-fetoprotein (αFP), lactase de- very suspicious for epithelial ovarian tumors while hydrogenase (LDH). On ultrasound, cell tumors, granulosa and theca-cell tumors. In Chapters 1 and 11 you can find inhibin and estradiol (granulosa cell tumors often more details of examination and ultrasound in produce estradiol and cause endometrium ovarian masses. DIAGNOSIS PREVENTION AND SCREENING Good history taking, a thorough physical examina- Primary prevention would save many lives. Overall survival remains low in advanced recto-vaginal examination to exclude an ovarian stages. The predictive value of the combination of mass in the pouch of Douglas. Attempts should 346 Ovarian Cancer be made to rule out the possibility of non- no adjuvant chemotherapy is indicated) or whether gynecological causes of pelvic masses. Very few the disease is in advanced stage and needs to be low-income countries have access to highly treated with systemic chemotherapy. In young technological diagnostic apparatus such as compu- patients with early FIGO stage IA tumor who want terized tomography (CT) scans and magnetic to remain fertile, the contralateral ovary and uterus resonance imaging (MRI). Their use should, even can be left in situ but an infracolic omentectomy when available, serve as adjuncts to diagnosis. A de- and optimal staging procedure should always be finitive preoperative diagnosis is usually not possible, performed in cases of epithelial ovarian cancer. Devel- In advanced-stage ovarian cancer (FIGO stage IIB– opment of other biomarkers of diagnose ovarian IV), primary debulking surgery or debulking sur- cancer at earlier stages is awaited. Survival outcomes are related to the MANAGEMENT OF EPITHELIAL OVARIAN success of the cytoreductive surgery: CANCER • Complete debulking: a complete resection of all Patients with early-stage ovarian cancer (stage I– macroscopic tumor lesions improves the disease- IIA) need a staging procedure, while patients with free and overall survival and is the goal of cyto- advanced disease need a debulking procedure. Therefore at diagnostic surgery of the >1 cm3 are left behind after surgery. When it turns out that the is suggested to improve efficacy of systemic chemo- mass is malignant, the patients should have an opti- 12 therapy. The best results are achieved when mal surgical staging procedure to rule out spread surgery is performed by a gynecologic oncologist of the disease. Where facilities are available, the experienced in ovarian cancer surgery, usually laparoscopic approach is an alternative for diagnosis those who perform more than 10 ovarian cancer and staging. The procedure for In early ovarian cancer (FIGO stage I–IIA) an debulking surgery is: open the abdomen with a optimal staging procedure (see Appendix 1 for a midline incision and carefully systematically assess systematic approach) must be performed, consisting the pelvis as well as the upper abdomen. Both ova- of: a midline incision in order to assess the pelvis as ries, tubes, the uterus and the omentum are resected well as the upper abdomen; removal of the affected and all other macroscopic tumor lesions are re- ovary, the contralateral ovary and the uterus; care- moved if feasible. This can include bowel surgery, ful inspection and palpation of all peritoneal sur- splenectomy or diaphragm stripping. Blood loss faces; peritoneal washing for cytology analysis; and morbidity of debulking surgery may be major biopsy sampling of any suspicious areas, such as and for this reason these procedures should be done adhesions adjacent to the primary tumor; infracolic by an experienced gynecologic oncologist.
Injections were performed without ultrasound guidance at the point of maximal tenderness with 5 needle penetrations in a peppering technique safe anacin 525mg. Rehabilitation for both groups was 24 hours of rest followed by 2 weeks of stretching and then an eccentric exercise program purchase anacin 525mg line. The primary outcome measure was a 25% reduction in the Disabilities of the Shoulder, Arm, and Hand (DASH) score, a validated functional outcome score for the upper extremity. Results of this study showed that 73% of the PRP group and 49% of the corticosteroid group met the primary outcome measure at 1 year. The corticosteroid group had initial relief of pain and improvement Hematology 2013 621 622 American Society of Hematology Figure 2. DASH scores at 1 year in the PRP and corticosteroid groups in the Peerbooms et al study. The primary outcome measure was 8 weeks; however, by 12 weeks, the scores were nearly identical, the percentage of patients who rated their treatment as “good or after which time the corticosteroid group returned to near baseline excellent” as measured by the modiﬁed Blazina scale and an but the PRP group continued to improve. This cohort was followed improvement on the Victorian Institute Sport Assessment-Patella for an additional year and there was continued improvement in the (VISA-P), a validated pain and functional activity scale for patellar PRP group without similar improvement in the corticosteroid group tendon injury analogous to that used for the Achilles. The third randomized controlled trial was by Krogh et al comparing PRP (n 20), saline (n 20), and corticosteroid (n 20). There are 4 for 25 months; however, the PRP and saline group had only had randomized controlled studies but their numbers are small. Three of symptoms for 17 months whereas the corticosteroid group had these studies show beneﬁt from PRP and one did not have an end symptoms for 36 months. The primary outcome measure was the point long enough to assess whether PRP was effective. Conclu- Patient Rated Tennis Elbow Evaluation (PRTEE) score, a validated sions that can be drawn at this point are that PRP should be pain and function score for the elbow. This study was initially considered after other conservative treatments have failed, in designed to look at outcomes at 6 months and 1 year; however, more particular eccentric exercises. In addition, if effective, PRP takes 3 than half of the study participants in all groups had dropped out by 6 to 6 months to show beneﬁt, but healing can continue out to 2 years. At 1 month, the corticosteroid group had better PRTEE activity modiﬁcation, which may adversely affect both physical and scores than the other groups; however, at 3 months, all groups had mental health. More research is needed, such as studies that include statistically equivalent scores. At the time the study was ended, the corticosteroid group was returning toward its baseline and the PRP group was trending toward improvement. It is PRP in arthritis unfortunate that 6- and 12-month data were not available as in other OA is a degenerative disease of the joints that affects the articular 6,12,14,25 cartilage, synovium, and subchondral bone. The complex The fourth randomized controlled study examined PRP versus balance of growth factors and cytokines involved in the regula- ESWT for chronic patellar tendinopathy. The average age in but PRP has been proposed as a physiologic combination of this study was 26 years, with an average duration of symptoms of 18 growth factors that can favorably affect the joint milieu in months. A 22-ga needle was used to inject LR-PRP with ultrasound osteoarthritic joints, thus halting or reversing the process. The ESWT group had 3 sessions 48 to 72 signiﬁcant impact on quality of life have sought out alternative hours apart. One week after the last treatment session, a standard and emerging treatments and have embraced the concept of a stretching and strengthening protocol was started, with a return to biologic treatment for this disease. Hematology 2013 623 PRP and other biologics have long been used in race horses with OA, and there are basic science studies suggesting why it use may be efﬁcacious; however, there are currently only 8 studies on the clinical use of PRP in OA in humans28-35 (Table 3) and all these studies have examined the effect of PRP in the osteoarthritic knee. None has reported any major adverse effect with the use of PRP and all have reported modest beneﬁt on validated functional outcome scales. It is difﬁcult to compare studies because they use different injection protocols and different types of PRP; however, Patel et al recently published a randomized, double-blind, placebo-controlled study supporting the use of PRP in OA of the knee. The 1 injection of LP-PRP was a higher platelet concentration, 10 baseline, than the 2 injection protocol, which was 4 baseline. Patients were followed at 6 weeks after the last injection at 3 and 6 months. There was a signiﬁcant improvement in all subscales of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores, as well as signiﬁcant improvements in the visual analog pain score. The scores were best at 3 months and regressed slightly at 6 months, but were still well above baseline compared with the saline group, which worsened over the 6 months from the initial baseline scores. Although the literature on the use of PRP is limited, initial clinical studies suggest a beneﬁt in knee OA. Its mechanism of action is also unknown, that is, whether it is purely pain relieving or if it stops or slows progression of further cartilage degradation or could reverse damage. More studies are needed in this area, including quantitative measurements of pre- and posttreatment articular cartilage on MRI and measurements of synovial and joint ﬂuid growth factors and cytokines. The possibili- ties of new treatments for this common and debilitating disease are intriguing. IL-1RA in OA Whereas it is not truly PRP, treatments with IL-1RA are being sought out for OA. IL-1 is thought to be a primary mediator of the breakdown of articular cartilage in degenerative joints.